Detalles de la búsqueda
1.
Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
Cancer Metastasis Rev
; 42(2): 481-505, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37022618
2.
Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond.
Int J Mol Sci
; 22(18)2021 Sep 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34576054
3.
Tumor-stroma contact ratio - a novel predictive factor for tumor response to chemoradiotherapy in locally advanced oropharyngeal cancer.
Transl Oncol
; 46: 102019, 2024 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-38833784
4.
Response to primary chemoradiotherapy of locally advanced oropharyngeal carcinoma is determined by the degree of cytotoxic T cell infiltration within tumor cell aggregates.
Front Immunol
; 14: 1070203, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37187729
5.
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.
J Immunother Cancer
; 11(9)2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37730278
6.
Nanodrugs Targeting T Cells in Tumor Therapy.
Front Immunol
; 13: 912594, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35693776
7.
Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?
Cancers (Basel)
; 14(7)2022 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35406483
8.
The Role of the Immune Phenotype in Tumor Progression and Prognosis of Patients with Mycosis Fungoides: A Quantitative Immunohistology Whole Slide Approach.
Cells
; 11(22)2022 11 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36428999
9.
The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma-A Retrospective, Real-World Cohort Study.
Cancers (Basel)
; 14(9)2022 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35565212
10.
Neutrophil-Specific Knockdown of ß2 Integrins Impairs Antifungal Effector Functions and Aggravates the Course of Invasive Pulmonal Aspergillosis.
Front Immunol
; 13: 823121, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35734179
11.
eHealth Literacy in German Skin Cancer Patients.
Int J Environ Res Public Health
; 19(14)2022 07 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35886215
12.
Impaired Treg-DC interactions contribute to autoimmunity in leukocyte adhesion deficiency type 1.
JCI Insight
; 7(24)2022 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36346673
13.
Protease- and cell type-specific activation of protease-activated receptor 2 in cutaneous inflammation.
J Thromb Haemost
; 20(12): 2823-2836, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36161697
14.
ß2 Integrins on Dendritic Cells Modulate Cytokine Signaling and Inflammation-Associated Gene Expression, and Are Required for Induction of Autoimmune Encephalomyelitis.
Cells
; 11(14)2022 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35883631
15.
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry.
Cancers (Basel)
; 14(22)2022 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36428636
16.
Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors.
ACS Nano
; 16(3): 4426-4443, 2022 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35103463
17.
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment.
Cancers (Basel)
; 13(2)2021 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33430105
18.
Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study.
Cancers (Basel)
; 13(20)2021 Oct 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34680252
19.
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges.
Target Oncol
; 16(5): 537-552, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34554353
20.
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.
Cancers (Basel)
; 13(10)2021 May 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34065877